Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry

Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry

Abstract Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which high-risk women are likely to be using endocrine ris...

Full description

Bibliographic Details
Main Authors: Yash S. Huilgol, Holly Keane, Yiwey Shieh, Robert A. Hiatt, Jeffrey A. Tice, Lisa Madlensky, Leah Sabacan, Allison Stover Fiscalini, Elad Ziv, Irene Acerbi, Mandy Che, Hoda Anton-Culver, Alexander D. Borowsky, Sharon Hunt, Arash Naeim, Barbara A. Parker, Laura J. van ‘T Veer, Athena Breast Health Network Investigators and Advocate Partners, Laura J. Esserman
Format: Article
Language:English
Published: Nature Publishing Group 2021-08-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00306-9

Internet

https://doi.org/10.1038/s41523-021-00306-9

Similar Items